Narkolepsie nach Impfung gegen die pandemische Influenza A/H1N1/v?

Doris Oberle; Geert Mayer; Brigitte Keller-Stanislawski

doi:10.1055/s-0038-1626061

Schlaf, Inhaltsverzeichnis

Schlaf 2013; 2(03): 154-160
DOI: 10.1055/s-0038-1626061

REVIEW Narkolepsie nach A/H1N1/v-Impfung?

Schattauer GmbH

Narkolepsie nach Impfung gegen die pandemische Influenza A/H1N1/v?

Doris Oberle

,

Geert Mayer

,

Brigitte Keller-Stanislawski

Abstract

Im Herbst/Winter 2009/2010 wurden etwa 30,8 Mio. Menschen in der Europäischen Union mit Pandemrix^® gegen die pandemische Influenza A/H1N1/v geimpft. Der von GlaxoSmithKline produzierte Impfstoff war im September 2009 von der Europäischen Kommission als Pandemieimpfstoff zugelassen worden. Im Sommer 2010 wurde erstmals über Fälle einer Narkolepsie bei Kindern und Jugendlichen nach Impfung mit Pandemrix^® in Schweden und Finnland berichtet.

Volltext

Referenzen

Literatur
1 Longstreth Jr. WT, Koepsell TD, Ton TG, Hendrickson AF. van BG The epidemiology of narcolepsy. Sleep 2007; Jan; 30 (01) 13-26.
2 Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 2002; Mar 15; 25 (02) 197-202.
3 Wijnans L, Lecomte C, de VC, Weibel D. et al. The incidence of narcolepsy in Europe: Before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013; 31 (08) 1246-1254.
4 Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998; Feb; 50 (02) (Suppl. 01) S16-S22.
5 Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M. et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; Sep; 27 (03) 469-474.
6 Savvidou A, Knudsen S, Olsson-Engman M, Gammeltoft S, Jennum P, Palm L. Hypocretin deficiency develops during onset of human narcolepsy with cataplexy. Sleep 2013; Jan; 36 (01) 147-148.
7 Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; Sep; 6 (09) 991-997.
8 Thannickal TC, Nienhuis R, Siegel JM. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep 2009; Aug; 32 (08) 993-998.
9 Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; Mar 6; 92 (05) 1.
10 Mieda M, Sakurai T. Overview of orexin/hypocretin system. Prog Brain Res 2012; 198: 5-14.
11 Inutsuka A, Yamanaka A. The regulation of sleep and wakefulness by the hypothalamic neuropeptide orexin/hypocretin. Nagoya J Med Sci 2013; Feb; 75 (1–2): 29-36.
12 Rogers AE, Meehan J, Guilleminault C, Grumet FC, Mignot E. HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy. Neurology 1997; Jun; 48 (06) 1550-1556.
13 Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997; Nov; 20 (11) 1012-1020.
14 Hallmayer J, Faraco J, Lin L, Hesselson S, Winkelmann J, Kawashima M. et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009; Jun; 41 (06) 708-711.
15 Faraco J, Lin L, Kornum BR, Kenny EE, Trynka G, Einen M. et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet 2013; 9 (02) e1003270.
16 Aran A, Lin L, Nevsimalova S, Plazzi G, Hong SC, Weiner K. et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009; Aug; 32 (08) 979-983.
17 Cvetkovic-Lopes V, Bayer L, Dorsaz S, Maret S, Pradervand S, Dauvilliers Y. et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest 2010; Mar; 120 (03) 713-719.
18 Anaka S, Honda Y, Inoue Y, Honda M. Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy. Sleep 2006; May; 29 (05) 633-638.
19 Deloumeau A, Bayard S, Coquerel Q, Dechelotte P, Bole-Feysot C, Carlander B. et al. Increased immune complexes of hypocretin autoantibodies in narcolepsy. PLoS One 2010; 5 (10) e13320.
20 MPA. Occurrence of narcolepsy with cataplexy among children and adolescents in relation to the H1N1 pandemic and Pandemrix vaccinations. Results of a case inventory study by the MPA in Sweden during 2009–2010. http://www.lakemedelsverket.se/upload/nyheter/2011/Fallinventeringsrapport_pandermrix_110630.pdf. 2013
21 Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J. et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012; 7 (03) e33536.
22 National Narcolepsy Study Steering Committee. Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010. http://www.dohc.ie/publications/Nat_Narcolespy_Study_SC_Report.html. 2013
23 European Centre for Disease Control and Prevention. Narcolepsy in association with pandemic influenza vaccination – a multi-country European epidemiological investigation. http://www.ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=959. 2013
24 Etude Narco Flu-VF (NarcoFlu VAESCO-France). Grippe, vaccination antigrippale et narcolepsie : contribution française à l’étude cas-témoins européenne. http://ansmsante. fr 2012 Sep 20.
25 Miller E, Andrews N, Stellitano L, Stowe J, Winstone AM, Shneerson J. et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013; 346: f794.
26 Szakacs A, Darin N, Hallbook T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 2013; Apr 2; 80 (14) 1315-1321.
27 Heier MS, Gautvik KM, Wannag E, Bronder KH, Midtlyng E, Kamaleri Y. et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med 2013; Jun 14.
28 MPA. Registerstudie med fokud pa neurologiska och immunrelaterade sjukdomar efter vaccination med Pandemrix. http://www.lakemedelsverket.se/upload/nyheter/2013/PDX%20Rapport%20SV%20-%20registerstudie%207%20landsting%20regioner%202013–03–26.pdf. 2013
29 THL. Increased risk of narcolepsy observed also among adults vaccinated with Pandemrix in Finland. http://www.thl.fi/en_US/web/en/pressrelease?id=33516. 2013
30 Paul-Ehrlich-Institut. Deutschlandweite Narkolepsiestudie. http://www pei de/DE/arzneimittelsicherheit-vigilanz/pharmakovigilanz/forschung/narkolepsie-studie/narkolepsie-studie-inhalt.html. 2013
31 Oberle D, Pönisch C, Mayer G, Keller-Stanislawski B. Fall-Kontroll-Studie zu Risikofaktoren von Narkolepsie in Deutschland. Somnologie 2013; 17 (01) 39-48.
32 Mahlios J, De la Herran-Arita AK, Mignot E. The autoimmune basis of narcolepsy. Curr Opin Neurobiol 2013; May 29.
33 Waldenlind L, Grundmark B, Azarbayjani F, Borjesson A, Olaisson H. Is the risk of narcolepsy also increased with non-adjuvanted flu vaccines?. BMJ 2013; 346: f2769.
34 Europäische Arzneimittelagentur (EMA). Empfehlung der Europäischen Arzneimittelagentur EMA, die Anwendung des pandemischen Impfstoffs Pandemrix bei Personen unter 20 Jahren einzuschränken. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/07/news_detail_001312.jsp&murl=menus/ news_and_events/news_and_events.jsp&mid= WC0b01ac058004d5c1. 2013